Regenxbio (NASDAQ:RGNX)‘s stock had its “buy” rating reissued by analysts at Raymond James Financial in a note issued to investors on Friday.

A number of other equities research analysts also recently weighed in on RGNX. TheStreet downgraded Regenxbio from a “c” rating to a “d+” rating in a research report on Tuesday, November 28th. Chardan Capital raised their price target on Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Bank of America raised their price target on Regenxbio from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, September 21st. BidaskClub raised Regenxbio from a “buy” rating to a “strong-buy” rating in a report on Friday, December 22nd. Finally, ValuEngine downgraded Regenxbio from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Regenxbio presently has an average rating of “Buy” and an average price target of $42.43.

Shares of Regenxbio (NASDAQ:RGNX) traded down $0.60 during trading hours on Friday, hitting $35.20. The company had a trading volume of 249,800 shares, compared to its average volume of 336,600. The company has a market cap of $1,115.00, a P/E ratio of -13.04 and a beta of -0.88. Regenxbio has a 52 week low of $16.30 and a 52 week high of $36.45.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.04. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. The business had revenue of $1.34 million during the quarter. sell-side analysts expect that Regenxbio will post -2.71 EPS for the current fiscal year.

In related news, CFO Vittal Vasista sold 5,000 shares of Regenxbio stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $33.25, for a total transaction of $166,250.00. Following the completion of the transaction, the chief financial officer now directly owns 92,283 shares in the company, valued at $3,068,409.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Curran Simpson sold 2,000 shares of Regenxbio stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $29.31, for a total value of $58,620.00. Following the transaction, the senior vice president now owns 41,500 shares of the company’s stock, valued at $1,216,365. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 114,000 shares of company stock valued at $3,646,446. Company insiders own 17.00% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc grew its holdings in Regenxbio by 41.4% in the second quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 2,011 shares during the period. Ardsley Advisory Partners purchased a new stake in Regenxbio during the 2nd quarter valued at approximately $197,000. Voya Investment Management LLC purchased a new stake in Regenxbio during the 2nd quarter valued at approximately $249,000. Asymmetry Capital Management L.P. raised its stake in Regenxbio by 12.2% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 1,508 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Regenxbio by 1.1% during the 2nd quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock worth $320,000 after buying an additional 175 shares in the last quarter. 68.73% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Raymond James Financial Reiterates Buy Rating for Regenxbio (RGNX)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/05/raymond-james-financial-reiterates-buy-rating-for-regenxbio-rgnx.html.

Regenxbio Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.